Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

77 results about "Collagen i" patented technology

Recombinant I-type humanized collagen with crosslinking property as well as preparation method and application of recombinant I-type humanized collagen

The invention relates to a recombinant I-type humanized collagen with crosslinking property as well as a preparation method and application thereof, and belongs to the technical field of recombinant proteins. The invention relates to recombinant I-type humanized collagen with crosslinking property. The amino acid sequence of the recombinant I-type humanized collagen comprises an amino acid sequence as shown in SEQ ID No.1 or a derivative amino acid sequence with the sequence identity of more than 90% with the sequence as shown in SEQ ID No.1; the recombinant I-type humanized collagen has a triple helix structure. A complete triple helix structure can be efficiently expressed, and the hydrogel has efficient cross-linking capability, so that the hydrogel can be efficiently and stably formed through cross-linking.
Owner:BEST PHARM (GUANGZHOU) CO LTD

Application of aromatic sulfonamide compound in preparation of medicine for preventing and treating liver injury

The invention provides application of an aromatic sulfonamide compound in preparation of a medicine for preventing and treating liver injury. The aromatic sulfonamide compound BC2059 provided by the invention can be used for inhibiting transcription and protein synthesis of related genes of Fibronectin and CollagenI in hepatic stellate cells, and plays a role in treating liver injury mice induced by bile duct ligation and carbon tetrachloride. The invention provides a potential drug molecule with a new action mechanism for treating liver injury.
Owner:ZHEJIANG UNIV +1

Application of anti-aging repairing polypeptide in cosmetics

The invention discloses application of anti-aging repairing polypeptide in cosmetics, and particularly relates to the technical field of cosmetics. The anti-aging repair polypeptide delays and inhibits the synthesis of interleukin-6, stimulates the synthesis of laminin V and collagen IV and VII, promotes the synthesis of collagen I, and inhibits the activity of acetylcholine receptors, calcium, sodium, potassium and other ion channels through a plurality of action mechanisms. The effects jointly enable the skin to be tight and elastic, reduce the problems of wrinkles, skin laxity and uneven skin color, and meanwhile repair the skin and relax muscles to improve and relieve the wrinkles.
Owner:SHANGHAI KETAI BIOLOGY TECH CO LTD

Type I humanized collagen as well as preparation method and application thereof

The invention relates to the technical field of biological medicine, in particular to I-type humanized collagen as well as a preparation method and application thereof. The amino acid sequence of the type I humanized collagen prepared by the invention is shown as a sequence SEQ ID NO. 1 (HTGAWGKTVIEYKTTKTSRLVMGFXGPKGAA, wherein X is hydroxyproline). The invention also discloses a preparation method of the type I humanized collagen. The I-type humanized collagen contains essential amino acids and semi-essential amino acids of a human body, promotes proliferation of human skin fibroblasts, up-regulates expression of elastin, fibronectin and collagen I genes, and has the effects of interacting with endothelial cells and osteoblasts, promoting creeping and growth of the osteoblasts, and promoting the growth of the osteoblasts. And the interaction between osteoblasts and collagen is promoted. Therefore, the I-type humanized collagen can be widely applied to orthopedic sports materials and has application prospects in the fields of medical cosmetology and sports medicine materials.
Owner:CHANGCHUN SINOBIOMATERIALS CO LTD

Anti-wrinkle composition, application thereof and cosmetic

The invention belongs to the technical field of cosmetics, and provides an anti-wrinkle composition, application thereof and cosmetics. The composition provided by the invention comprises acetylated sodium hyaluronate and acetyl hydroxyproline, and the mass part ratio of the acetylated sodium hyaluronate to the acetyl hydroxyproline is (0.2-40): 1. In the composition provided by the invention, the acetylated sodium hyaluronate and the acetyl hydroxyproline have a synergistic anti-wrinkle effect, and the effect of the composition is obviously greater than the sum of the effects of the acetylated sodium hyaluronate and the acetyl hydroxyproline which are independently used in the aspect of promoting the synthesis of the fibroblast collagen I. When the composition with the synergistic anti-wrinkle effect provided by the invention is applied to preparation of cosmetics, the use amount of acetyl hydroxyproline can be reduced, so that the cost is reduced, and meanwhile, remarkable anti-wrinkle and anti-aging effects are obtained.
Owner:SHANGHAI HUARUI WANMEI BIOTECHNOLOGY CO LTD +1

Application of eclipta-derived extracellular vesicles

The invention discloses an application of eclipta source extracellular vesicles. The extracellular vesicles are extracted from the eclipta by adopting an overspeed combined ultrafiltration centrifugation method, and the extracted vesicles are complete in morphology and good in dispersity, and have the characteristics of high yield, high separation speed, low cost and easiness in large-scale production. The extracted vesicles can be successfully taken by animal cells. The yerbadetajo herb alcohol extract has the advantages that the yerbadetajo herb alcohol extract has antioxidant and anti-aging effects after being taken in, ultraviolet-induced matrix metalloproteinase 1 (MMP1) expression can be obviously reduced, collagen I (COL-I) generation can be promoted, ultraviolet-induced skin light aging can be improved, and the effect is better than that of the yerbadetajo herb alcohol extract, so that the yerbadetajo herb alcohol extract can be used for preparing the skin The eclipta-derived extracellular vesicles provided by the invention provide a new strategy for skin aging and anti-aging treatment.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

Preparation method and application of novel rhizoma bletillae glucomannan

The invention relates to a preparation method and application of novel rhizoma bletillae glucomannan. The preparation method of the rhizoma bletillae glucomannan comprises the following steps: 1, drying, crushing and sieving rhizomes of a raw material rhizoma bletillae; 2, putting the crushed and sieved rhizoma bletillae into ethanol for degreasing; 3, obtaining crude polysaccharide through a distilled water ice bath ultrasonic extraction technology and an ethanol precipitation technology; 4, separating and purifying through a DEAE-52 cellulose column and a G-150 gel column to obtain the high-purity rhizoma bletillae homogeneous polysaccharide BsPsIII1-1, namely the rhizoma bletillae glucomannan; 5, carrying out semipermeable membrane dialysis on the BsPsIII1-1 to remove salt, and carrying out freeze drying; and 6, carrying out chemical analysis on the obtained BsPsIII1-1. According to the preparation method and the application of the novel rhizoma bletillae glucomannan, animal experiments show that BsPsIII1-1 can significantly improve CCl4 induced mouse liver tissue injury, reduce serum ALT and AST levels, effectively relieve oxidative stress by reducing MDA content and increasing GSH level, and significantly inhibit hepatic fibrosis by down-regulating expression of alpha smooth muscle actin (alpha-SMA) and collagen I (COL-1).
Owner:ZUNYI MEDICAL UNIVERSITY

Use of phosphodiesterase 5 inhibitor in preparation of medicament for resisting fibrotic diseases

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.
Owner:SHENZHEN HANHUI PHARM TECH CO LTD

A skin cell repair and anti-wrinkle composition and preparation method thereof

The present invention discloses a skin cell repair anti-wrinkle composition and a preparation method thereof, which specifically belongs to the technical field of skin care products. The skin cell repair anti-wrinkle composition includes ingredients including skin conditioning components, composite functional oils and emulsifiers, wherein the skin conditioning components are sea fennel extract, unicorn extract, oligopeptide-1, sea red bean extract, cape aloe leaf extract and ebony bark extract, and the composite functional oils are brown-spotted pit viper oil and black tea seed oil; the repair anti-wrinkle composition can effectively promote collagen I synthesis and effectively inhibit the activity of elastase; the resident skin topical preparation provided by the present invention has excellent firming and anti-wrinkle effects, and the skin topical preparation has a high lactic acid stinging improvement rate and has a good repair effect.
Owner:SHENZHEN ZHISUI TECHNOLOGY CO LTD

Application of MAPK1IP1L gene or MAPK1IP1L protein as action target in preparation of medicine for treating chronic kidney disease

The invention relates to the technical field of biological medicines, in particular to application of an MAPK1IP1L gene or an MAPK1IP1L protein serving as an action target to preparation of a medicine for treating chronic kidney disease. According to the invention, the MAPK1IP1L gene overexpression (MAPK1IP1L OE) HK2 cell is constructed, and compared with a group in which the HK2 cell is not treated, the MAPK1IP1L OE has the advantage that the protein expression levels of FN, Collagen I, Vimentin and alpha-SMA are obviously reduced. Therefore, the chronic kidney disease can be improved and treated by overexpressing the MAPK1IP1L gene. Therefore, the invention relates to the application of the MAPK1IP1L gene or the MAPK1IP1L protein as the action target spot in preparation and / or screening of the medicine for treating the chronic kidney disease.
Owner:ZHEJIANG CHINESE MEDICAL UNIVERSITY

Collagen-like material and application thereof

The invention discloses a collagen-like material and application thereof, and belongs to the fields of biology and genetic engineering. The invention designs a self-assembled collagen mimic peptide (collagen-like) with functions of promoting blood coagulation, cell regeneration and osteoblast differentiation, and realizes recombinant expression and fermentation production of the collagen-like in escherichia coli. The prepared collagen-like material can form hydrogel at the concentration of more than or equal to 0.08 g / L. The invention also verifies the effects of the collagen-like compound on the aspects of promoting blood coagulation, cell regeneration and osteoblast differentiation. The collagen-like compound provided by the invention shows the blood coagulation capability superior to that of a commercial blood coagulation agent rat tail collagen I, and has huge value and potential in the fields of cosmetics, medicine and tissue engineering.
Owner:JIANGNAN UNIV

Anti-aging composition as well as preparation method and application thereof

The invention discloses an anti-aging composition as well as a preparation method and application thereof. The composition is prepared from the following components in parts by weight: 10 to 50 parts of ergothioneine; 5 to 25 parts of coenzyme Q10; 50 to 150 parts of 3-SL; 50 to 150 parts of collagen tripeptide; 100 to 500 parts of NAD (nicotinamide adenine dinucleotide); and 50 to 150 parts of glutathione. According to the anti-aging composition disclosed by the invention, various functional components such as the ergothioneine, the coenzyme Q10, the 3SL, the collagen tripeptide, the NAD < + > and the glutathione are reasonably proportioned, so that the anti-aging composition shows a remarkable synergistic anti-aging effect in in-vitro and in-vivo experiments. The anti-aging composition can enhance the cell antioxidant capacity, reduce the active oxygen level and promote the expression of collagen I and SIRT1, and compared with a single component or a non-optimized combination, the anti-aging effect is remarkably improved.
Owner:WHEAT LIFE (SHENZHEN) SCIENCE CO LTD

Azolo compounds for treatment of fibrotic diseases

The present invention relates to an azolo compound of Formula (I) for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFB-activated fibroblasts and reverses collagen production to the normal levels that are seen in fibroblasts that are not stimulated.
Owner:GEORG AUGUST UNIVERSITAT GOTTINGEN STIFTUNG OFFENLICHEN RECHTS

Application of arabinoxylan in preparation of medicine for treating chronic obstructive pulmonary disease

The invention discloses application of arabinoxylan (AX) in preparation of a medicine for treating chronic obstructive pulmonary disease (COPD), and belongs to the technical field of medicines. The arabinoxylan (AX) can be used for preparing a medicine for treating the COPD (chronic obstructive pulmonary disease). Through a large number of researches, the inventor of the application finds that AX has a remarkable COPD treatment effect: lung inflammation in a mouse COPD model caused by haze can be reduced, the expression is that infiltration of mature T lymphocytes and macrophages in lung tissues is reduced, and the expression level of various proinflammatory factors including TGF-beta1 is reduced; the compound can weaken extracellular matrix deposition in the lung of a COPD mouse caused by haze, reduce the thickness of a tracheal wall, and reduce the expression of I-type collagen (collagen I) and a myofibroblast marker smooth muscle alpha2-actin (alpha-Sma); the emphysema degree of a COPD mouse induced by haze is also relieved; the AX also relieves abnormal changes of related protein levels of iron metabolism, mitochondrial metabolism, oxidative stress and glycometabolism in the lung tissue of the COPD mouse induced by haze. Therefore, AX can be used for preparing the medicine for treating COPD.
Owner:HEBEI NORMAL UNIV

Immunoassay for detecting collagen i fragment

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.
Owner:NORDIC BIOSCIENCE AS

Method for scar-free healing in treatment of wound surface / wound by miR-185-5p

The invention discloses a method for scar-free healing in treatment of wounds / wounds by miR-185-5p, relates to the field of biological medicine and plastic surgery and beauty repair, and comprises application of scar-free healing in acute / subacute / chronic wounds related to any skin injury (including burn, laceration, bruise, operation, perforation and vaccination) of deep dermis. Wound healing is a series of complex and elaborately-planned overlapping stages arranged according to a time sequence, wherein the stages comprise four stages of hemostasis, inflammation, proliferation and remodeling. No matter at any stage, the skin stability after wound healing and whether scars are formed or not can be directly influenced. The miR-185-5p is used in an animal skin model caused by an acute wound, so that the wound healing time is integrally shortened, the reepithelization formation of the wound is promoted, the number of skin appendages is increased, and the regeneration of hair follicles is promoted. The secretion amount of the collagen I is reduced, and the formation of the collagen III is improved.
Owner:HENGFENG MINGCHENG BIOTECHNOLOGY (SHANGHAI) CO LTD

Azolo compounds for treatment of fibrotic diseases

The present invention relates to an azolo compound of Formula I for use in the treatment of fibrosis, wherein the azolo compounds normalizes collagen I mRNA-levels of TGFB-activated fibroblasts and reverses collagen production to the normal levels that are seen in fibroblasts that are not stimulated.
Owner:GEORG AUGUST UNIVERSITAT GOTTINGEN STIFTUNG OFFENLICHEN RECHTS

Bone organ with autonomous mineralization ability and preparation and application thereof

The invention relates to the technical field of preparation of organoid, in particular to a bone organoid with autonomous mineralization ability as well as preparation and application of the bone organoid. The preparation method comprises the following steps: firstly, uniformly mixing Matrigel matrigel with a Collagen I working solution to obtain an organ-like matrix working solution; then suspending the osteogenesis precursor cell line in an organ-like matrix working solution, placing in a PDMS (Polydimethylsiloxane) chip, solidifying, and soaking by using an alpha-MEM culture solution containing 10% FBS to obtain a bone organ; and finally, carrying out osteogenesis induction treatment on the bone organ by utilizing an osteogenesis induction culture solution to obtain the bone organ with autonomous mineralization ability. The prepared bone organ with the autonomous mineralization ability can be further applied to the medical fields of disease model preparation, drug screening or bone tissue regeneration.
Owner:SHANGHAI STOMATOLOGICAL HOSPITAL FUDAN UNIV

Type I collagen coating method for promoting cell adherent proliferation

The invention discloses an I-type collagen coating method for promoting cell adherent proliferation, and belongs to the technical field of cell culture. According to the method, collagen is not prone to falling off, no obvious adverse effect is generated on the biological activity of the collagen, and coating is easy and fast, 60%-80% (v / v) ethyl alcohol is used as a solvent to dissolve or dilute the collagen I, and a collagen I solution is obtained; the culture vessel is coated with the I-type collagen solution as a coating solution, the culture vessel coated with the I-type collagen is obtained, the whole process is carried out at room temperature, a specific environment does not need to be provided, the defect that an existing traditional coating mode needs to be carried out under ice is overcome, and the culture vessel can be used for promoting cell proliferation and adhesion, is suitable for culture of various cells and has good application prospects. And the cost is reduced.
Owner:SAINING (SUZHOU) BIOTECHNOLOGY CO LTD

Short peptide composition, recombinant polypeptide chain, recombinant nucleic acid molecule and application

The invention discloses an oligopeptide composition, a recombinant polypeptide chain, a recombinant nucleic acid molecule and application. The oligopeptide composition comprises at least one oligopeptide, the amino acid sequence of the oligopeptide is the amino acid sequence of an active domain of HAPLN1 protein, and the oligopeptide composition is used for improving the expression quantity of fibroblasts on the HAPLN1 protein and collagen I.
Owner:上海致臻志臣科技有限公司

Polycyclic polyketone derivative as well as preparation method and application thereof in treatment of hepatic fibrosis

The invention belongs to the technical field of medical chemistry, and particularly relates to a polycyclic polyketone derivative as well as a preparation method and application thereof in treating hepatic fibrosis. Six polycyclic polyketone compounds are obtained from a fungus M. arundinis HL1 separated from a marine sample in Huilaxian County, Guangdong Province, the series of compounds can significantly inhibit expression of FN, Collagen I, alpha-SMA and other fibrosis-related factors in hepatic stellate cells LX-2, and the compound 2 has a significant inhibition effect at a concentration of 40 [mu] mol / L and has no significant toxicity. And the compound 2 reduces the p-Smad2 / 3 level through dose dependence, does not influence the total Smad2 / 3 level, and plays an anti-fibrosis role by inhibiting a TGF-beta / Smad signal channel. The series of compounds, especially the compound 2, are expected to become anti-hepatic fibrosis candidate drugs, and provide a brand new chemical skeleton for research and development of low-toxicity and high-efficiency anti-hepatic fibrosis drugs.
Owner:SUN YAT SEN UNIV

Application of benzbromarone in preparation of medicine for treating pulmonary fibrosis

The invention discloses a new application of benzbromarone or pharmaceutically acceptable salt thereof in preparation of a medicine for treating pulmonary fibrosis. The invention belongs to the technical field of medicine. Experimental results show that the benzbromarone can significantly reduce collagen deposition and inflammatory infiltration in lung tissues, reduce fibrosis area, improve lung functions of patients with pulmonary fibrosis, inhibit lung fibroblast activation and inhibit fibrosis progress. The action mechanism of the gene is related to inhibition of expression of BAG2, FN1, Collagen I and protein. The invention provides a brand new medicine choice for treating pulmonary fibrosis, has the unique advantage of new use of old medicine, and has the potential of short research and development period, known safety and definite curative effect. Meanwhile, the invention further expands the application of benzbromarone in preparation of the protein inhibitor and the in-vitro reagent.
Owner:HARBIN MEDICAL UNIVERSITY

Azo compounds for treatment of fibrotic diseases

The present invention relates to an azo compound of formula (I) for use in the treatment of fibrosis wherein the azo compound normalizes the collagen I mRNA levels of TGF [beta]-activated fibroblasts and reverses the production of collagen to normal levels in unstimulated fibroblasts # imgabs0 #
Owner:GEORG AUGUST UNIVERSITAT GOTTINGEN STIFTUNG OFFENLICHEN RECHTS

Application of gray fleece honeysuckle saponin A in preparation of products for promoting skin wound repair and regeneration

The application discloses application of sibiricose A in preparation of products for promoting skin wound repair and regeneration. The application finds through experiments that sibiricose A can promote proliferation and migration of fibroblasts and vascular endothelial cells, promote lumen formation of vascular endothelial cells, and promote fibroblasts to secrete collagen I, can accelerate wound healing, promote more blood vessels and collagen to be generated, reduce secretion of pus and inflammatory substances, has the ability to promote skin wound repair and treat chronic ulcers, and provides an effective way for skin wound repair and regeneration, especially for repair and regeneration of diabetic refractory wounds.
Owner:JINAN UNIVERSITY

Application of glipizide in preparing drugs for treating liver fibrosis

The present invention provides the use of glipizide in the preparation of a drug for treating liver fibrosis. The present invention proves that glipizide can reduce CCl 4 Induced liver fibrosis in mice, hematoxylin-eosin (HE), Sirius red staining, and immunohistochemical detection of the expression of Collagen Ⅰ and α-SMA were used to verify the therapeutic effect of glipizide on liver fibrosis. Glipizide can be used as a promising drug for the treatment of liver fibrosis.
Owner:SCNU QINGYUAN INSTITUTE OF SCIENCE & TECHNOLOGY INNOVATION CO LTD

Preparation methods for islet extracellular matrix scaffold and biomimetic islet organoid thereof, and use thereof

PCT designated stageWO2025246807A1ProsthesisCollagen iCell-Extracellular Matrix
Provided are preparation methods for an islet extracellular matrix scaffold and a biomimetic islet organoid. The scaffold is a gel, and the gel contains 3-5 mg / mL Collagen I, 3-5 mg / mL Collagen IV, and 0.8-1.2 mg / mL Laminin. For the scaffold, Collagen I, Collagen IV, and Laminin are simultaneously selected as extracellular matrix components, which have relatively strong interactions with islet cells, and effectively promote the islet cells and enhance insulin secretion function stimulated by glucose after binding to the islet cells. Collagen VI can also be used. Collagen VI can act on the islet cells to effectively enhance the survival of the islet cells and the insulin secretion function stimulated by glucose. The gel can form a relatively intact network structure without needing to use a cross-linking agent, thereby enhancing the support capacity for the islet organoid.
Owner:GUANGDONG GENERAL HOSPITAL

A combination of cancer prognosis markers and use thereof

The application belongs to the technical field of medical treatment and discloses a cancer prognosis marker combination and application thereof, which comprises the following markers: CD68, PD-L1, PAN-CK, HLA-DR, CD45, CD11c and Collagen I. The cancer prognosis evaluation model trained by using the 7-marker combination exhibits superior prognosis accuracy compared to a model relying on high-dimensional multi-omics data. The application proposes a multiple immunohistochemistry (mIHC) cancer prognosis evaluation detection product based on the above-mentioned cancer prognosis marker combination. Satisfactory prognosis results are achieved by using only two five-marker combinations. The method exhibits high accuracy in predicting the survival of gastric cancer patients, so that it becomes a low-cost, high-benefit and scalable solution for other cancers.
Owner:HANGZHOU INPHITOMICS BIOTECHNOLOGY CO LTD +2

Application of eustachys japonicus extracellular vesicles

The application discloses application of extracellular vesicles from Eclipta prostrata L. The extracellular vesicles are extracted from Eclipta prostrata L. by using ultracentrifugation and ultrafiltration, and the extracted vesicles are complete in appearance and good in dispersibility, and have the characteristics of high yield, fast separation, low cost and easy scaling. The extracted vesicles can be successfully taken by animal cells. After being taken, the vesicles play the roles of antioxidation and anti-aging, can significantly reduce ultraviolet-induced matrix metalloproteinase 1 (MMP1) expression, promote collagen I (COL-I) generation, improve ultraviolet-induced skin photoaging, and the effect is stronger than that of Eclipta prostrata L. alcohol extract, so that the extracellular vesicles from Eclipta prostrata L. provide a new strategy for skin aging and anti-aging treatment.
Owner:THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV

A Gardenia Polysaccharide, Its Preparation Method and Application

This invention provides a gardenia polysaccharide, its preparation method, and its application in the preparation of drugs for treating pulmonary fibrosis, relating to the fields of traditional Chinese medicine extracts and biomedical technology. This invention extracts a novel polysaccharide structure, GP121, from gardenia. The extraction method for GP121 provided by this invention is simple, with high polysaccharide extraction rate and low production cost. This invention further studies the anti-pulmonary fibrosis bioactivity of GP121 at the cellular level. The results show that GP121 provided by this invention can delay the fibrosis process of MRC-5 cells induced by TGF-β1, thereby slowing the fibrosis process by inhibiting the phosphorylation of Smad3 protein and thus reducing the expression of α-SMA, Collagen I, and FN proteins. GP121 provided by this invention can serve as a potential therapeutic drug for pulmonary fibrosis, providing a new application of gardenia polysaccharide in the treatment of pulmonary fibrosis.
Owner:HENAN UNIV OF CHINESE MEDICINE

Immunoassay for detecting collagen i fragment

The present invention relates to methods of immunoassay for detecting a biomarker which is an MMP-cleaved fragment of collagen type-I and its use in detecting and / or monitoring diseases such as kidney disease and diseases of the cardiovascular system including the heart.
Owner:NORDIC BIOSCIENCE AS